Dr. Xudong Huang is an Associate Professor of Psychiatry at Harvard Medical School (HMS) and he co-directs Neurochemistry Laboratory of Psychiatry Department at the Massachusetts General Hospital (MGH). His current research thrusts are centered upon: (i) validating potential link of environmental stressors such as exposure of metals and engineered nanomaterials (ENMs) and neurodegeneration; (ii) performing Alzheimer’s disease (AD)-related gene expression and image data analysis using clinical data and machine learning (ML)-based biomedical Big Data analytics; (iii) discovering novel theranostics and nutraceuticals for neurodegenerative and psychiatric diseases such as AD and depression. Among others, Dr. Huang collaborates with researchers within the MGH Psychiatry Department and from pharmaceutical and biotechnology industry. In particular, Dr. Huang has launched an artificial intelligence (AI)-based virtual drug discovery program based on a signed research agreement between MGH and Atomwise, Inc. Other collaborators include those at the Broad Institute of MIT and Harvard, and the Boston University School of Medicine (BUSM). Dr. Huang has more than 100 publications in reputed journals and 5 issued patents, and he has been serving as the Editor-in-Chief for the International Journal of Biomedical Nanoscience and Nanotechnology (IJBNN). In addition, Dr. Huang has been a manuscript reviewer for more than 50 research journals and a grant reviewer for private foundations and government agencies including Alzheimer’s Association, American Federation for Aging Research (AFAR), and NIH. Dr. Huang was previously trained as a chemist. He received a PhD in Nuclear Science & Engineering from MIT and performed his postdoctoral work at Neurology and Psychiatry Departments of MGH and HMS.